Advertisement

Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin

Published:December 02, 2016DOI:https://doi.org/10.1016/j.ejim.2016.11.016
      I read with great interest the paper by Ellis et al. [
      • Ellis M.H.
      • Neuman T.
      • Bitterman H.
      • Dotan S.G.
      • Hammerman A.
      • Battat E.
      • et al.
      Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study.
      ], which is a retrospective cohort study to determine the incidence of bleeding in patients with atrial fibrillation (AF) beginning dabigatran, rivaroxaban or warfarin during 3-year. Bleeding incidences were calculated per 100 patient-years of treatment, and they were 3.9 (95% confidence interval (CI), 3.6–4.4) in warfarin patients, 4.2 (95% CI, 3.7–4.7) in dabigatran patients, and 4.1 (95% CI, 3.0–5.3) in rivaroxaban patients. In addition, intracranial hemorrhage (ICH) rates were 0.71 (95% CI, 0.56–0.90) in warfarin patients, 0.4 (95% CI, 0.18–0.87) in dabigatran patients, and 0.27 (95%CI, 0.10–0.80) in rivaroxaban patients. The authors recognized no significant differences in the prevalence of bleeding and ICH in dabigatran and rivaroxaban patients against warfarin patients. I have some queries on their study.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ellis M.H.
        • Neuman T.
        • Bitterman H.
        • Dotan S.G.
        • Hammerman A.
        • Battat E.
        • et al.
        Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study.
        Eur J Intern Med. 2016; 33: 55-59
        • Lip G.Y.
        • Pan X.
        • Kamble S.
        • Kawabata H.
        • Mardekian J.
        • Masseria C.
        • et al.
        Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States.
        Int J Clin Pract. 2016; 70: 752-763
        • Camm A.J.
        • Amarenco P.
        • Haas S.
        • Hess S.
        • Kirchhof P.
        • Kuhls S.
        • et al.
        XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
        Eur Heart J. 2016; 37: 1145-1153
        • Tamayo S.
        • Frank Peacock W.
        • Patel M.
        • Sicignano N.
        • Hopf K.P.
        • et al.
        Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27,467 patients taking rivaroxaban.
        Clin Cardiol. 2015; 38: 63-68
        • Coleman C.I.
        • Antz M.
        • Bowrin K.
        • Evers T.
        • Simard E.P.
        • Bonnemeier H.
        • et al.
        Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
        Curr Med Res Opin. 2016; 32: 2047-2053